BIONEWS
A new joint report from Boston Consulting Group and India focused health venture fund HealthKois counts 10+ novel drug assets advanced by Indian pharma in a decade, but a small home market means the bet is to invent here and license abroad.
Wockhardt's recent run of overseas drug approvals has come from a company most Americans have never heard of. The Mumbai-based drugmaker is one of three Indian pharma firms, alongside Glenmark and Zydus, that the country's newest innovation report names as the operational evidence that "green shoots" in Indian drug R&D have broken the surface.
That report, a joint effort by Boston Consulting Group (BCG) and the Indian health venture fund HealthKois, makes a concrete claim: in the past decade, internal R&D at Indian pharma companies has advanced more than 10 novel drug assets, meaning newly invented compounds rather than copies of existing medicines. The same companies have grown their pharma innovation pipeline to 1,095 programmes, up roughly 1.5x, while private equity and venture capital funding to the segment has jumped 2.1x to $731 million, per coverage in FierceBiotech.
Western pharmas typically advance more than 10 novel assets in a single year, so the 10+ count from Indian internal R&D over a decade is small in absolute terms. Co-author Priyanka Aggarwal calls the count the difference between a flatline and a phase change: "It's not a large number, but it's substantially better than before."
India's largest listed drugmakers have, in Aggarwal's account, reached a $40-50 billion market-cap tier where the cost of running a credible discovery lab stops being a vanity project and starts being a normal line item. Co-author Ajay Mahipal told FierceBiotech that at that size, "it makes so much more sense to get into the discovery game."
The Wockhardt-Glenmark-Zydus bet is whether India's long-running generics and vaccines base can compound into original invention. By volume, the country is the world's third-largest drug producer, supplying roughly 40% of U.S. generic demand and about 60% of global vaccine production. The manufacturing base is real; the question is whether the R&D base can catch up.
The phase change has not solved the original problem, and the report's authors say so on the record. Indian pharma companies have historically faced a chicken-and-egg bind: novel R&D needs deep pockets, and deep pockets for novel R&D historically meant a domestic market large enough to absorb the launches. India's domestic drug market is large by population but small per capita relative to the U.S. Aggarwal describes how prior Indian innovators ran out of home-currency revenue before their first molecule reached an FDA review.
The substitute the report points to is out-licensing: selling the rights to a novel drug candidate to a global pharma partner that runs the expensive late-stage trials and global commercialization, in exchange for milestone payments and royalties. Glenmark's recent high-value out-licensing deals and Wockhardt's overseas approvals are the operational evidence that this substitution is closing deals, not just filling slide decks. Indian Pharma Post's separate write-up tracks the same 10+ novel asset count and corroborates the report's argument.
Two caveats apply. First, the report is a sponsored joint product of BCG and HealthKois, and both co-authors are on the record promoting its findings. The 10+ novel assets figure and the 1,095-programme count are the report's own data, not independent third-party audits of Indian pharma pipelines. Fortune India's coverage corroborates the headline numbers, but neither Fortune India nor Indian Pharma Post independently audited the underlying pipeline counts.
Second, the report's $40-50 billion "upper echelon" tier is loosely defined. India's largest listed pharma companies have varied widely in market cap over the past 12 months, and the report's tier description isn't tied to a specific BSE/NSE (Bombay Stock Exchange / National Stock Exchange) snapshot. Any company-specific market-cap claim in derivative coverage should be checked against current exchange data before publication.
The next marker is deal flow, not pipeline counts. If one of the named innovators, whether Wockhardt, Glenmark, or Zydus, closes an out-licensing deal with a global pharma partner at a publicly disclosed value above the prior generation of Indian out-licensing benchmarks, the substitution model has its first test passed. Two or three such deals in a 12-month window would graduate "green shoots" from a count to a trend. If the deal flow thins, the 10+ novel asset count reads as a lucky decade rather than a new normal.
The historical blocker Aggarwal names, namely deep pockets required for novel R&D and a small home market to pay for it, is still the right question to keep on the table. The 2024-2026 evidence so far shows the cap-threshold part of that equation has moved. The substitution-of-out-licensing-for-domestic-demand part is the bet the next two years are pricing.